What Is Cagrilintide? The Long-Acting Amylin Analogue

Cagrilintide is Novo Nordisk’s long-acting amylin analogue, carried through development under the codes AM833 and NN9838. It is a lipidated 37-amino-acid peptide built on the pramlintide backbone, engineered to act at amylin and calcitonin receptors for a once-weekly interval rather than the minutes-long window of native amylin. Most of what is publicly known comes from a compact but well-documented body of primary literature — a medicinal-chemistry design paper, in-vitro receptor pharmacology, and a ladder of phase 1 through phase 3 trials. Everything below describes laboratory and literature findings, not use in people.

What is cagrilintide, chemically?

Cagrilintide is a synthetic acylated peptide with the molecular formula C194H312N54O59S2 and a molecular weight of roughly 4409 Da¹³. It carries the CAS number 1415456-99-3 and the development codes AM833 and NN9838. The medicinal-chemistry paper that describes its design (compound 23 in that work) frames it as a long-acting amylin analogue derived not from native human amylin but from pramlintide, the synthetic amylin analogue already in clinical use¹.

The design choice matters. Native human amylin is notoriously prone to forming amyloid fibrils, which complicates its use as a therapeutic backbone. Pramlintide substitutes several residues to reduce that aggregation tendency, and cagrilintide builds further on that platform, adding a lipid (fatty-acid) modification. The lipidation is the engineering lever for half-life: pramlintide has a reported half-life of about 48 minutes and requires thrice-daily injection, whereas the acylated cagrilintide was deliberately designed to support a once-weekly interval in the trials¹. In short, the molecule is an exercise in taking a well-characterised but short-lived hormone class and extending its duration while suppressing its worst physical-chemistry liability.

37 amino acids, one lipid chain — cagrilintide is a small, precisely engineered peptide, not a large biologic.

How does it work — the amylin/calcitonin receptor mechanism?

Cagrilintide is a dual amylin/calcitonin receptor agonist. Its in-vitro pharmacology was characterised under the name AM833 in a study that compared it against six selective and non-selective agonists across the calcitonin receptor family². That work established agonism across the amylin receptors (AMY1–3) and at the calcitonin receptor itself.

The receptor architecture is worth spelling out, because it is where the amylin class diverges from the more familiar incretin drugs. Amylin receptors are not standalone proteins. They are formed from the calcitonin receptor in complex with receptor activity-modifying proteins (RAMPs); the specific RAMP that associates with the calcitonin receptor determines which amylin receptor subtype (AMY1, AMY2, or AMY3) is presented. This is laid out in the authoritative IUPHAR review of the calcitonin/CGRP receptor family⁹. Because cagrilintide engages this calcitonin-receptor-derived system, its mechanism is pharmacologically distinct from GLP-1 receptor agonism — a different receptor, a different signalling context. That distinction is the entire reason amylin analogues are studied as a complementary rather than redundant approach.

The class itself has a name in the literature: dual amylin and calcitonin receptor agonists, or DACRAs. Cagrilintide is one member, and the same receptor pharmacology is being explored well beyond metabolism — a recent review examines DACRAs in the context of osteoarthritis, which underscores that the defining feature is receptor engagement, not a single disease indication¹².

Amylin receptors are the calcitonin receptor plus a RAMP — which is why cagrilintide’s mechanism sits in a different pharmacological family from the GLP-1 drugs it is often studied alongside.

What does amylin actually do?

Amylin (islet amyloid polypeptide) is a hormone secreted by pancreatic beta cells, co-released with insulin in response to nutrient intake. Its studied physiological roles include satiation signalling, slowing of gastric emptying, and modulation of glucagon¹⁰¹¹. Narrative and historical accounts of amylin biology position it as a distinct axis from the incretin hormones — a separate lever on energy balance and glucose handling that operates through the amylin/calcitonin receptor system rather than the GLP-1 pathway¹¹. That physiological separation is what makes an engineered, long-acting amylin analogue interesting as a research tool.

What does the trial literature cover?

The clinical development literature for cagrilintide forms a fairly clean ladder. The first-in-combination phase 1b trial (Enebo, Lau, and colleagues) reported the pharmacokinetics, pharmacodynamics, safety, and tolerability of cagrilintide co-administered with semaglutide 2.4 mg — the pairing referred to in the literature as CagriSema³. A separate phase 2 dose-finding trial studied cagrilintide as monotherapy, testing once-weekly doses from 0.3 to 4.5 mg against both placebo and an active comparator, liraglutide 3.0 mg, in overweight and obesity research⁴. That monotherapy trial is the main source for what the amylin analogue does on its own, and it defined the compound’s dose-dependent profile and tolerability.

The combination programme then extended into type 2 diabetes with a phase 2 CagriSema trial⁵, and advanced to phase 3 under the REDEFINE banner. REDEFINE 1 examined the cagrilintide-semaglutide combination in adults with overweight or obesity⁶; REDEFINE 2 studied it in a type-2-diabetes population⁷; and REDEFINE 5 tested the combination against semaglutide alone in East Asian populations⁸. Across all of these, semaglutide appears only as a combination partner or active comparator — the amylin analogue is cagrilintide.

All entries describe published clinical-trial reports. These are literature findings, not dosing guidance; Condor supplies cagrilintide for in-vitro / laboratory research only.

An honest read of the evidence

Cagrilintide is an investigational compound, and the evidence base should be read with that firmly in mind. The phase 1 through phase 3 trials cited here report research outcomes and were largely sponsor-run by Novo Nordisk, the developer. That is normal for a compound at this stage, but it means most of the human clinical data comes from the developer and its collaborators; there is limited fully independent replication of efficacy claims outside the sponsor programme. Independent characterisation of the pharmacology exists — the AM833 receptor work² is the anchor — but that study is in-vitro, transfected-cell pharmacology. Extrapolating cell-based potency and selectivity to whole-organism effects is inherently limited, and nothing in that assay speaks to what happens in an intact animal, let alone anything beyond it.

The combination design carries its own interpretive caveat. The CagriSema and REDEFINE trials test cagrilintide together with semaglutide, so combination outcomes cannot be attributed to the amylin analogue alone. The cleanest read on cagrilintide by itself is the phase 2 monotherapy dose-finding trial⁴, which is earlier-stage and, by design, exploratory. Tolerability is a recurring, honestly reported limitation: gastrointestinal effects such as nausea and vomiting — typical of both amylin- and incretin-class agents — appear across the trials and should be acknowledged rather than glossed over. Finally, long-term safety and outcome data beyond the trial windows are not established. The literature is still maturing, with several of the key phase 3 readouts dated 2025 and 2026⁶⁷⁸. The picture is coherent and reasonably well documented for a compound of this age, but it is not a closed case.

All materials supplied by Condor Research are Research Use Only (RUO). Everything above reflects in-vitro and published-literature findings and is not a dosing protocol, clinical guidance, or a safety assessment for any organism. Nothing here describes or endorses human or veterinary use.

Condor Research · Wissenschaftlicher Support
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com